Tyro Capital Management LLC Boosts Position in Establishment Labs Holdings Inc. $ESTA

Tyro Capital Management LLC boosted its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 1.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,077,456 shares of the company’s stock after purchasing an additional 10,735 shares during the period. Establishment Labs comprises 16.4% of Tyro Capital Management LLC’s investment portfolio, making the stock its largest position. Tyro Capital Management LLC owned 3.71% of Establishment Labs worth $44,165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. State of Wyoming bought a new position in shares of Establishment Labs in the third quarter worth approximately $71,000. Osaic Holdings Inc. raised its holdings in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares during the last quarter. Brian Low Financial Group LLC bought a new stake in Establishment Labs during the 3rd quarter valued at $223,000. Private Advisor Group LLC boosted its position in Establishment Labs by 14.1% during the 3rd quarter. Private Advisor Group LLC now owns 5,450 shares of the company’s stock valued at $223,000 after buying an additional 675 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC boosted its position in Establishment Labs by 5.8% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company’s stock valued at $261,000 after buying an additional 350 shares during the period. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. BTIG Research boosted their price objective on shares of Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. increased their target price on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. Citigroup upped their price target on Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Finally, Needham & Company LLC increased their price objective on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $87.00.

Establishment Labs Price Performance

Shares of ESTA stock opened at $69.06 on Tuesday. The business’s fifty day moving average is $70.81 and its 200 day moving average is $60.03. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -39.69 and a beta of 0.91. Establishment Labs Holdings Inc. has a twelve month low of $26.56 and a twelve month high of $83.31.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The company’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter last year, the firm posted ($1.19) earnings per share. Research analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.